Leerink spot­lights No­var­tis’ late-stage stars plus one util­i­ty play­er — sug­gest­ing where it could make deals

Over the last year No­var­tis has been build­ing a rep as some­thing of a pen­ny pinch­er among the phar­ma gi­ants. It’s ex­tend­ed its rest­less search for new ef­fi­cien­cies in­to R&D, carv­ing out pock­ets of in­ves­ti­ga­tors as it cen­tral­izes its work in the big hubs. And it’s al­so adopt­ed a grow-your-own ap­proach to some of the ther­a­peu­tics it wants to have.

Case in point: PD-1.

Sea­mus Fer­nan­dez

In a re­view of its late-stage pipeline with Leerink’s Sea­mus Fer­nan­dez, com­pa­ny ex­ecs high­light­ed the phar­ma gi­ant’s PDR001, one of a num­ber of check­points aimed at the PD-(L)1 ax­is in can­cer drug de­vel­op­ment. Un­like Mer­ck, Bris­tol-My­ers Squibb, Roche, Pfiz­er and As­traZeneca, though, No­var­tis isn’t so much boast­ing about its stand­alone po­ten­tial as it is just bring­ing along a check­point of its own for the fu­ture com­bos that it plans to of­fer.

Now PDR001 is in Phase III with Mekin­ist and Tafin­lar, the two can­cer drugs it swapped for with Glax­o­SmithK­line. And ex­ecs high­light­ed its part­ner­ship with Aduro $ADRO on ADU-S100 — part of its col­lab­o­ra­tion on STING path­way ac­ti­va­tor com­pounds — as an ex­am­ple of the kind of de­vel­op­ment pro­gram it can get ex­cit­ed about.

So what else is go­ing on at No­var­tis?

Af­ter a qui­et pe­ri­od of re­view, No­var­tis is clear­ly pumped about its lead­ing CAR-T work. As Leerink notes, No­var­tis has a clear lead for now in its dri­ve to win a land­mark OK for CTL019 in pe­di­atric acute lym­phoblas­tic leukemia, with a near-term fo­cus on dif­fuse large B-cell lym­phoma and chron­ic lym­pho­cyt­ic leukemia. Past that, as we wrote about ear­li­er in the week, CTL119 is show­ing strong po­ten­tial as a next-gen can­di­date in the CAR-T field.

Ev­i­dent­ly we’re just weeks away from get­ting Phase III da­ta on RTH258, an an­ti-VEGF for age-re­lat­ed mac­u­lar de­gen­er­a­tion. This is a tough field, though, so mere sta­tis­ti­cal sig­nif­i­cance will not be enough to make this one a ma­jor new block­buster for No­var­tis. The com­pa­ny is look­ing at dos­es every eight weeks and twelve weeks, and be­lieves it needs to get at least 40% of pa­tients in­to the more con­ve­nient twelve-week dos­es to make a suc­cess of the drug.

Joe Jimenez

A few weeks ago No­var­tis CEO Joe Jimenez out­lined a very care­ful set of rules on any new ac­qui­si­tions, specif­i­cal­ly draw­ing the line at $5 bil­lion on most any new buy. With Tesaro $TSRO back in the news with a po­ten­tial auc­tion, No­var­tis made it clear that it would like a PARP, IDO and BTK drug, but “val­u­a­tions were too high to jus­ti­fy a ma­jor deal in the (PARP) space.”

Tesaro, with its new­ly ap­proved PARP, has a mar­ket val­u­a­tion of $8 bil­lion. In­cyte $IN­CY, a leader in IDO, tips the scales at $26 bil­lion. And that gives you some idea of what No­var­tis means about val­u­a­tions right now.

Like a lot of the phar­ma ma­jors, No­var­tis is pay­ing rapt at­ten­tion to the de­bate over drug pric­ing in the US. And there’s a way they want to see this play out. First, fo­cus on:

(1) sys­temic in­ef­fi­cien­cies built around Phar­ma­cy Ben­e­fit Man­agers (PBMs) and pay­ers; and (2) the need for cre­ative pric­ing strate­gies with­in Medicare and Med­ic­aid, specif­i­cal­ly in­ter­est in out­come-based pric­ing, which could be fa­cil­i­tat­ed by a waiv­er to the Med­ic­aid best price reg­u­la­tions. Over­all, mgmt. ap­peared hope­ful that the ad­min­is­tra­tion would in­clude so­lu­tions to these is­sues in its up­com­ing pro­pos­al and be­lieves that drug re-im­por­ta­tion is un­like­ly to be­come a re­al­i­ty in the near fu­ture.

Norbert Bischofberger. Kronos

Backed by some of the biggest names in biotech, Nor­bert Bischof­berg­er gets his megaround for plat­form tech out of MIT

A little over a year ago when I reported on Norbert Bischofberger’s jump from the CSO job at giant Gilead to a tiny upstart called Kronos, I noted that with his connections in biotech finance, that $18 million launch round he was starting off with could just as easily have been $100 million or more.

With his first anniversary now behind him, Bischofberger has that mega-round in the bank.

Endpoints News

Basic subscription required

Unlock this story instantly and join 55,000+ biopharma pros reading Endpoints daily — and it's free.

Francesco De Rubertis

Medicxi is rolling out its biggest fund ever to back Eu­rope's top 'sci­en­tists with strange ideas'

Francesco De Rubertis built Medicxi to be the kind of biotech venture player he would have liked to have known back when he was a full time scientist.

“When I was a scientist 20 years ago I would have loved Medicxi,’ the co-founder tells me. It’s the kind of place run by and for investigators, what the Medicxi partner calls “scientists with strange ideas — a platform for the drug hunter and scientific entrepreneur. That’s what I wanted when I was a scientist.”

Endpoints News

Basic subscription required

Unlock this story instantly and join 55,000+ biopharma pros reading Endpoints daily — and it's free.

Af­ter a decade, Vi­iV CSO John Pot­tage says it's time to step down — and he's hand­ing the job to long­time col­league Kim Smith

ViiV Healthcare has always been something unique in the global drug industry.

Owned by GlaxoSmithKline and Pfizer — with GSK in the lead as majority owner — it was created 10 years ago in a time of deep turmoil for the field as something independent of the pharma giants, but with access to lots of infrastructural support on demand. While R&D at the mother ship inside GSK was souring, a razor-focused ViiV provided a rare bright spot, challenging Gilead on a lucrative front in delivering new combinations that require fewer therapies with a more easily tolerated regimen.

They kept a massive number of people alive who would otherwise have been facing a death sentence. And they made money.

And throughout, John Pottage has been the chief scientific and chief medical officer.

Until now.

Endpoints News

Basic subscription required

Unlock this story instantly and join 55,000+ biopharma pros reading Endpoints daily — and it's free.

On a glob­al romp, Boehringer BD team picks up its third R&D al­liance for Ju­ly — this time fo­cused on IPF with $50M up­front

Boehringer Ingelheim’s BD team is on a global deal spree. The German pharma company just wrapped its third deal in 3 weeks, going back to Korea for its latest pipeline pact — this time focused on idiopathic pulmonary fibrosis.

They’re handing over $50 million to get their hands on BBT-877, an ATX inhibitor from Korea’s Bridge Biotherapeutics that was on display at a science conference in Dallas recently. There’s not a whole lot of data to evaluate the prospects here.

Endpoints News

Basic subscription required

Unlock this story instantly and join 55,000+ biopharma pros reading Endpoints daily — and it's free.

Novotech CRO Ex­pands Chi­na Team as Biotech De­mand for Clin­i­cal Tri­als In­creas­es up to 79%

An increase in demand of up to 79% for clinical trials in China has prompted Novotech the Asia-Pacific CRO to rapidly expand the China team, appointing expert local clinical executives to their Shanghai and Hong Kong offices. The company is planning to expand their team by 30% over the next quarter.

Novotech China has seen considerable demand recently which is borne out by research from GlobalData:
A global migration of clinical research is occurring from high-income countries to low and middle-income countries with emerging economies. Over the period 2017 to 2018, for example, the number of clinical trial sites opened by biotech companies in Asia-Pacific increased by 35% compared to 8% in the rest of the world, with growth as high as 79% in China.
Novotech CEO Dr John Moller said China offers the largest population in the world, rapid economic growth, and an increasing willingness by government to invest in research and development.
Novotech’s 23 years of experience working in the region means we are the ideal CRO partner for USA biotechs wanting to tap the research expertise and opportunities that China offers.
There are over 22,000 active investigators in Greater China, with about 5,000 investigators with experience on at least 3 studies (source GlobalData).

Servi­er scoots out of an­oth­er col­lab­o­ra­tion with Macro­Gen­ics, writ­ing off their $40M

Servier is walking out on a partnership with MacroGenics $MGNX — for the second time.

After the market closed on Wednesday MacroGenics put out word that Servier is severing a deal — inked close to 7 years ago — to collaborate on the development of flotetuzumab and other Dual-Affinity Re-Targeting (DART) drugs in its pipeline.

MacroGenics CEO Scott Koenig shrugged off the departure of Servier, which paid $20 million to kick off the alliance and $20 million to option flotetuzumab — putting a heavily back-ended $1 billion-plus in additional biobuck money on the table for the anti-CD123/CD3 bispecific and its companion therapies.

Den­mark's Gen­mab hits the jack­pot with $500M+ US IPO as small­er biotechs rake in a com­bined $147M

Danish drugmaker Genmab A/S is off to the races with perhaps one of the biggest biotech public listings in decades, having reaped over $500 million on the Nasdaq, as it positions itself as a bonafide player in antibody-based cancer therapies.

The company, which has long served as J&J’s $JNJ key partner on the blockbuster multiple myeloma therapy Darzalex, has asserted it has been looking to launch its own proprietary product — one it owns at least half of — by 2025.

FDA over­rides ad­comm opin­ions a fifth of the time, study finds — but why?

For drugmakers, FDA advisory panels are often an apprehended barometer of regulators’ final decisions. While the experts’ endorsement or criticism often translate directly to final outcomes, the FDA sometimes stun observers by diverging from recommendations.

A new paper out of Milbank Quarterly put a number on that trend by analyzing 376 voting meetings and subsequent actions from 2008 through 2015, confirming the general impression that regulators tend to agree with the adcomms most of the time — with discordances in only 22% of the cases.

UP­DAT­ED: With loom­ing ‘apoc­a­lypse of drug re­sis­tance,’ Mer­ck’s com­bi­na­tion an­tibi­ot­ic scores FDA ap­proval on two fronts

Merck — one of the last large biopharmaceuticals companies in the beleaguered field of antibiotic drug development — on Wednesday said the FDA had sanctioned the approval of its combination antibacterial for the treatment of complicated urinary tract and intra-abdominal infections.

To curb the rise of drug-resistant bacteria and maintain the efficacy of the therapy, Recarbrio (and other antibacterials) — the drug must be used to treat or prevent infections that are proven or strongly suspected to be caused by susceptible gram-negative bacteria, Merck $MRK said.

Endpoints News

Basic subscription required

Unlock this story instantly and join 55,000+ biopharma pros reading Endpoints daily — and it's free.